Pauline Lau, PhD

Bio:

Dr. Pauline Y. Lau is a pharmaceutical leader and biotech innovator with over 35 years of experience driving drug development, translational medicine, and clinical commercialization. As the Founder and CEO of Suntec Medical, she leads the strategic development of novel therapeutics for central nervous system (CNS) diseases, oncology, and autoimmune conditions.

Under Dr. Lau’s leadership, Suntec Medical is transforming CNS disease and cancer therapies using its proprietary "Multi-pathway, Immune-modulating, Nanocarrier, Combination-therapy" (MINC) platform.

Prior to founding Suntec, Dr. Lau spent over 20 years at Roche in senior executive roles, including Senior Director of Integrated Medicine. Her technical expertise spans translational biomarkers and clinical drug development across oncology, inflammation, and neurology. She played a critical role in developing key translational biomarkers for globally recognized immunotherapies and therapeutics, including Herceptin, Rituxan, Pegasys, Evista, and Forteo.

A recognized global expert, Dr. Lau has served as an advisor to the World Health Organization (WHO), consulted for the US FDA, and presented at over 100 international medical and biopharmaceutical conferences. She holds a PhD in Analytical Chemistry from the University of South Carolina and an MS in Biochemistry from Wayne State University.